$600.20
Value $279B
CAT and SRTA stock compared: price, dividend, valuation and results, from SEC filings.
$600.20
Value $279B
$5.51
Value $479M
Caterpillar (CAT) has a market value of $279B and Strata Critical Medical (SRTA) $479M. Over the last year, with dividends, CAT moved +5.6% and SRTA +8.0%. Dividend yield: CAT 1.02%, SRTA none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CAT$279B
SRTA$479M
CAT is 583 times SRTA
Revenue, 12 months
CAT$77.8B
SRTA$281M
CAT is 277 times SRTA
Net income, 12 months
CAT$11.8B
SRTA-$25M
Operating margin
CAT18.3%
SRTA-6.6%
24.9 points apart
ROIC
CAT21.1%
SRTA-5.2%
26.3 points apart
P/E
CAT23.6
SRTA–
Dividend yield
CAT1.0%
SRTA0.0%
1.0 points apart
5-year return
CAT+211.6%
SRTA-45.1%
256.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CAT+211.6%
SRTA-45.1%
| Period | CATWith dividends | SRTAWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +5.6%Price +4.7% | +8.0%Price +8.0% |
| 3 years since November 13, 2023 | +158.3%+37.2% a yearPrice +148.4% | +68.0%+18.9% a yearPrice +68.0% |
| 5 years since November 12, 2021 | +211.6%+25.5% a yearPrice +186.8% | -45.1%-11.3% a yearPrice -45.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CATCaterpillarSRTAStrata Critical Medical
| Price | $600.20 | $5.51 |
|---|---|---|
| Market value | $279B | $479M |
| Enterprise value (EV) | $314B | $438M |
| P/E | 23.6 | – |
| P/E, 5-year median | 17.5 | – |
| P/B | 13.0 | 1.7 |
| EV/EBIT | 22.0 | – |
| Free cash flow yield | 4.0% | 0.2% |
| Revenue, 12 months | $77.8B | $281M |
|---|---|---|
| Net income, 12 months | $11.8B | -$25M |
| Free cash flow, 12 months | $11.3B | $806.0K |
| Earnings per share, 12 months | $25.49 | -$0.30 |
| Revenue growth, year on year | 4.3% | 34.3% |
| Revenue growth a year, past | +10.1%over 5 years | +53.1%over 5 years |
| EPS growth a year, past | +28.1%over 5 years | – |
| Gross margin | 34.8% | 21.6% |
|---|---|---|
| Operating margin | 18.3% | -6.6% |
| Net margin | 15.2% | -8.8% |
| ROIC | 21.1% | -5.2% |
| ROE | 58.3% | -8.8% |
| Cash | $8.8B | $42M |
|---|---|---|
| Total debt | $43.3B | $3.6M |
| Net debt / EBITDA | 2.1 | – |
| Interest cover | – | – |
| Dividend yield | 1.0% | – |
|---|---|---|
| Dividend per share, 12 months | $6.13 | – |
| Dividend growth a year, past | +7.6%over 5 years | – |
| Buyback yield | 1.9% | – |
| Shareholder yield | 2.9% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Caterpillar ($279B) is about 582.7 times Strata Critical Medical ($479M), at today's prices.
Since November 12, 2021, CAT's price moved +186.8% and SRTA's -45.1%. With dividends: CAT +211.6% (+25.5% a year), SRTA -45.1% (-11.3% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.02% for Caterpillar and none for Strata Critical Medical. Over the last twelve months they paid $6.13 and – per share.
Over the last twelve months, the net margin was 15.2% for Caterpillar and -8.8% for Strata Critical Medical, and the operating margin 18.3% and -6.6%. Revenue was $77.8B and $281M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.